Page last updated: 2024-11-08

limonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
CitrusgenusA plant genus of the family RUTACEAE. They bear the familiar citrus fruits including oranges, grapefruit, lemons, and limes. There are many hybrids which makes the nomenclature confusing.[MeSH]RutaceaeA plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID179651
CHEMBL ID517449
CHEBI ID16226
SCHEMBL ID320315
MeSH IDM0041781

Synonyms (83)

Synonym
(4as,6ar,8ar,8br,9as,12s,12as,14ar,14br)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldecahydrooxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,8,10(1h,6h,8ah)-trione
BRD-K05906022-001-03-6
limonoic acid 3,19:16,17-dilactone
dictamnolactone
citrolimonin
limonoic acid, di-delta-lactone
limonoate d-ring-lactone
CHEBI:16226 ,
obaculactone
7,16-dioxo-7,16-dideoxylimondiol
(4as,6ar,8ar,8br,9as,12r,12as,14ar,14br)-12-(3-furyl)-6,6,8a,12a-tetramethyldecahydro-3h-oxireno[d]pyrano[4',3':3,3a][2]benzofuro[5,4-f]isochromene-3,8,10(6h,9ah)-trione
evodia fruit
ACON1_001996
nsc-36508
SDCCGMLS-0066837.P001
ai3-37932
limonine
11h,13h-oxireno(d)pyrano(4',3':3,3a)isobenzofuro(5,4-f)(2)benzopyran-4,6,13(2h,5ah)-trione, 8-(3-furyl)decahydro-2,2,4a,8a-tetramethyl-
nsc 36508
11h,13h-oxireno(d)pyrano(4',3':3,3a)isobenzofuro(5,4-f)(2)benzopyran-4,6,13(2h,5ah)-trione, 8-(3-furanyl)decahydro-2,2,4a,8a-tetramethyl-, (2ar,4ar,4br,5as,8s,8as,10ar,10br,14as)-
11h,13h-oxireno(d)pyrano(4',3':3,3a)isobenzofuro(5,4-f)(2)benzopyran-4,6,13(2h,5ah)-trione, 8-(3-furanyl)decahydro-2,2,4a,8a-tetramethyl-, (2ar-(2aalpha,4abeta,4br,5aalpha,8alpha,8aalpha,10aalpha,10br*,14aalpha))-
NCGC00178483-01
NCGC00178483-02
SPECTRUM5_000935
BSPBIO_002763
3-furyl(tetramethyl)[?]trione
limonoic acid di-.delta.-lactone
limonin ,
C03514
1180-71-8
evodin
limonin, from citrus seeds, >90% (hplc)
KBIO3_001983
KBIOGR_001659
SPECTRUM2_001728
SPECTRUM4_001140
SPBIO_001776
SPECTRUM3_001012
SPECTRUM1800018
limonoic acid 3,19:16,17 dilactone
limoni
dtxsid8045985 ,
dtxcid6025985
tox21_111513
cas-1180-71-8
CHEMBL517449
AKOS015965307
CCG-38796
l0f260866s ,
unii-l0f260866s
ccris 4047
limonoic acid di-delta-lactone
bdbm50418089
HY-17411
CS-1237
NCGC00178483-04
SCHEMBL320315
tox21_111513_1
NCGC00263659-01
KBDSLGBFQAGHBE-MSGMIQHVSA-N
Q-100083
limonoic acid, di-.delta.-lactone
limonin [mi]
(4as,6ar,8ar,8br,9as,12s,12as,14ar,14br)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldecahydro-1h,3h-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,8,10(6h,9ah)-trione
L0258
mfcd00075922
AC-8045
limonin, analytical standard
NCGC00178483-05
limone
S2319
rel-(4as,6ar,8ar,8br,9as,12s,12as,14ar,14br)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldecahydrooxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,8,10(1h,6h,8ah)-trione
1809582-56-6
Q2398745
AS-15249
BRD-K05906022-001-05-1
(4as,14br)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldecahydro-1h,3h-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,8,10(6h,9ah)-trione
limone; citrolimonin; evodine; dictamnolactone; obaculactone
NCGC00178483-14
A854522
(4as,6ar,8ar,8br,9as,12r,12as,14ar,14br)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldecahydro-3h-oxireno[d]pyrano[4',3':3,3a][2]benzofuro[5,4-f]isochromene-3,8,10(6h,9ah)-trione
(1r,2r,7s,10r,13r,14r,16s,19s,20s)-19-(furan-3-yl)-9,9,13,20-tetramethyl-4,8,15,18-tetraoxahexacyclo[11.9.0.02,7.02,10.014,16.014,20]docosane-5,12,17-trione
linonin

Research Excerpts

Overview

Limonin (LIM) is a natural medicine from citrus fruit that protects organs against ischemic diseases. Limonin is a bitter triterpenoid dilactone in the genus Citrus with potential medicinal value.

ExcerptReferenceRelevance
"Limonin (LIM) is a natural medicine from citrus fruit that protects organs against ischemic diseases, but the candidate genes and pathways associated with cardioprotection are unknown."( Identification of candidate genes and pathways in limonin-mediated cardiac repair after myocardial infarction.
Feng, S; Gong, J; Qing, S; Wang, H; Xiong, W; Yang, Y; Zeng, Z; Zhao, Y, 2021
)
1.6
"Limonin is a natural triterpenoid isolated from citrus fruit. "( Limonin mitigates cardiometabolic complications in rats with metabolic syndrome through regulation of the IRS-1/GLUT4 signalling pathway.
Jan-O, B; Maneesai, P; Pakdeechote, P; Phuthong, S; Poasakate, A; Rattanakanokchai, S; Tong-Un, T, 2023
)
3.8
"Limonin is a tetracyclic triterpenoid isolated from citrus fruits. "( Limonin ameliorates cardiovascular dysfunction and remodeling in hypertensive rats.
Iampanichakul, M; Khamseekaew, J; Maneesai, P; Pakdeechote, P; Potue, P; Rattanakanokchai, S; Settheetham-Ishida, W, 2023
)
3.8
"Limonin is a natural tetracyclic triterpenoid compound, which widely exists in "( Limonin: A Review of Its Pharmacology, Toxicity, and Pharmacokinetics.
Chen, Z; Fan, S; Luo, T; Tang, Y; Wang, J; Yu, L; Zhang, C, 2019
)
3.4
"Limonin is an abundant triterpenoid natural product and, through alteration of its heptacyclic core ring system using short synthetic sequences, a collection of 98 compounds was created, including multiple members with novel ring systems."( Limonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity.
Furiassi, L; Hergenrother, PJ; Tonogai, EJ, 2021
)
2.79
"Limonin is a bioactive compound that is traditionally extracted from citrus seeds using organic solvents or alkaline/metal ion solutions. "( Recovery and purification of limonin from pummelo [Citrus grandis] peel using water extraction, ammonium sulfate precipitation and resin adsorption.
Chen, F; Du, XP; Jiang, ZD; Li, LJ; Ni, H; Wu, LM; Yang, YF; Zhang, LZ; Zhang, SF, 2017
)
2.19
"Limonin is a bitter triterpenoid dilactone in the genus Citrus with potential medicinal value. "( Comprehensive characterization of the in vitro and in vivo metabolites of limonin in human samples using LC-Q-TOF/MS.
Chen, P; Dai, G; Fu, H; Ju, W; Li, C; Liu, S; Sun, L; Zhang, L; Zhang, N; Zhao, Y; Zhu, L, 2017
)
2.13
"Limonin is a triterpenoid in citrus seeds, which has significant biological activities. "( Biotransformation and Metabolic Profile of Limonin in Rat Liver Microsomes, Bile, and Urine by High-Performance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry.
Chen, D; Chen, P; Dai, G; Ju, W; Liu, S; Sun, B; Sun, L; Wang, Y; Zhang, L; Zhou, D; Zhu, L, 2018
)
2.19
"Limonin is a triterpenoid extracted from citrus which possesses the capacities to against inflammations and cell apoptosis."( Limonin ameliorates ulcerative colitis by regulating STAT3/miR-214 signaling pathway.
Chen, Y; Fu, H; Liu, S; Lu, J; Lv, X; Ren, C; Zeng, Z; Zhang, S; Zheng, L; Zhou, D; Zhou, X, 2019
)
2.68
"Limonin is a widely used dietary supplement and one of the most prevalent citrus limonoids, which are known to have inhibitory effects on CYPs and P-gp."( Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro.
Guo, C; Han, YL; Li, D; Meng, XL; Wang, FJ; Yu, HL; Yu, Q; Zhang, XY; Zhou, ZY, 2011
)
1.41
"Limonin, which is a weak enzyme inducer, was less potent as an inhibitor of BP-induced neoplasia."( Inhibition of benzo[a]pyrene-induced forestomach neoplasia in mice by citrus limonoids.
Hasegawa, S; Lam, LK, 1989
)
1

Effects

Limonin has been shown to exhibit anti-inflammatory and antioxidant properties in the settings of chemically induced hepatic injury. Its precise metabolism mechanism has not been well explored.

ExcerptReferenceRelevance
"Limonin has a potential protective function revealed by the metabolic profiling of limonin-treated rats located closer to the normal group."( Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis.
An, N; Meng, X; Sun, H; Wang, H; Wang, X; Yan, G; Zhang, A; Zhang, Y, 2015
)
1.38
"Limonin has received significant attention due to its multiple biological effects, intervertebral disc degeneration (IDD) is also of interest due to the high prevalence of this disease. "( Limonin delays the progression of intervertebral disc degeneration in vivo and in vitro: the key role of the MAPK/NF-κB and necroptosis pathways.
Chu, B; Gong, Y; Hong, Z; Jiang, T; Lu, F; Mi, S; Qiu, J; Sun, J; Xu, W; Yang, G; Ye, J; Zhang, W; Zheng, X, 2023
)
3.8
"Limonin has been shown to exert anti-inflammatory effects, however, its roles in tumor progression remain unclear. "( Limonin attenuates the stemness of breast cancer cells via suppressing MIR216A methylation.
Chang, D; Pei, J; Sai, C; Su, Z; Wang, C; Zhu, X, 2019
)
3.4
"Limonin has been shown to exhibit anti-inflammatory and antioxidant properties in the settings of chemically induced hepatic injury. "( Limonin attenuates hepatocellular injury following liver ischemia and reperfusion in rats via toll-like receptor dependent pathway.
El-Fayoumi, HM; Gamal, S; Mahmoud, MF, 2014
)
3.29
"Limonin has been found to possess significant anti-inflammatory properties in animal tests and with, human cells, however, its precise metabolism mechanism has not been well explored. "( Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis.
An, N; Meng, X; Sun, H; Wang, H; Wang, X; Yan, G; Zhang, A; Zhang, Y, 2015
)
2.1

Actions

ExcerptReferenceRelevance
"Limonin plays an important role in the regulation of inflammatory diseases, but it has not been reported in the treatment of intestinal injury and ulcers."( Limonin ameliorates indomethacin-induced intestinal damage and ulcers through Nrf2/ARE pathway.
Jia, B; Li, M; Liu, P; Tian, Z; Zhao, L, 2023
)
3.07

Pharmacokinetics

The rapid and sensitive method was fully validated and successfully applied to the pharmacokinetic study of limonin, dictamnine, obacunone and fraxinellone in the rat plasma.

ExcerptReferenceRelevance
" The method was successfully applied to pharmacokinetic study of limonin in dogs."( Determination of limonin in dog plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ju, WZ; Li, CY; Liu, SJ; Liu, ZX; Yu, BY; Zhang, J; Zhou, L, 2013
)
0.97
" This rapid and sensitive method was fully validated and successfully applied to the pharmacokinetic study of limonin, dictamnine, obacunone and fraxinellone in the rat plasma after oral administration of Cortex Dictamni extract."( Simultaneous determination of limonin, dictamnine, obacunone and fraxinellone in rat plasma by a validated UHPLC-MS/MS and its application to a pharmacokinetic study after oral administration of Cortex Dictamni extract.
Gao, E; Qu, W; Sun, J; Wang, P; Yu, Z; Zhao, Y, 2013
)
0.89

Bioavailability

The P-gp efflux and CYP3A4 metabolism were involved in the poor intestinal absorption and low bioavailability of limonin.

ExcerptReferenceRelevance
"0 g in 200 mL of buffered water) for the presence of limonin to establish the absorption, metabolism, and bioavailability of citrus limonoids to humans."( Bioavailability of citrus limonoids in humans.
Breksa, AP; Hasegawa, S; Jacob, RA; Manners, GD; Schoch, TK, 2003
)
0.57
" An earlier study on the bioavailability of limonin glucoside in humans had indicated that limonin glucoside was metabolized to give limonin and a second limonin metabolite."( Isolation and identification of the first C-17 limonin epimer, epilimonin.
Breksa, AP; Dragull, K; Wong, RY, 2008
)
0.86
" The P-gp efflux and CYP3A4 metabolism were involved in the poor intestinal absorption and low bioavailability of limonin."( [Transport of limonin in rat intestine in situ and Caco-2 cells in vitro].
He, L; Ke, X; Tian, JL; Zhang, XY, 2012
)
0.95
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The therapeutic efficacy of different limonin dosing protocols was evaluated in experimentally infected mice harboring Schistosoma mansoni. The exploration of the intestinal absorption mechanism is crucial to the design of dosage form.

ExcerptRelevanceReference
" The exploration of the intestinal absorption mechanism is crucial to the design of dosage form and clinical use of limonin."( [Transport of limonin in rat intestine in situ and Caco-2 cells in vitro].
He, L; Ke, X; Tian, JL; Zhang, XY, 2012
)
0.95
" In the current work, the therapeutic efficacy of different limonin dosing protocols was evaluated in experimentally infected mice harboring Schistosoma mansoni (Egyptian strain) juvenile or adult stages."( Dose-response relationship in Schistosoma mansoni juvenile and adult stages following limonin treatment in experimentally infected mice.
Abdallah, KF; Abou-Ouf, EA; Aly, NS; El-Kholy, AA; Eraky, MA; Hamdan, DI; Hammam, OA; Kishik, SM; Moharam, AF; Rashed, GA, 2016
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
volatile oil componentAny plant metabolite that is found naturally as a component of a volatile oil.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
inhibitorA substance that diminishes the rate of a chemical reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
limonoidAny triterpenoid that is highly oxygenated and has a prototypical structure either containing or derived from a precursor with a 4,4,8-trimethyl-17-furanylsteroid skeleton. The term 'limonoid' comes from limonin, the first tetranortriterpenoid obtained from citrus bitter principles.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
hexacyclic triterpenoidA triterpenoid that consists of a hexacyclic ring system.
furansCompounds containing at least one furan ring.
organic heterohexacyclic compound
lactoneAny cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency8.42970.000221.22318,912.5098AID743036; AID743040; AID743042; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.97720.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.32550.000214.376460.0339AID720691; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.41240.000229.305416,493.5996AID743079; AID743080
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency5.30800.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)19.14000.00022.318510.0000AID1555761
Cytochrome P450 3A4Homo sapiens (human)Ki23.20000.00011.41629.9000AID589117
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID1128808Partition coefficient, log D of the compound at pH 7.42014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID1695490Antiinflammatory activity in ICR mouse model of carrageenan-induced paw edema assessed as paw edema inhibition rate at 50 mg/kg, ig pretreated with compound followed by carrageenan challenge and measured after 4 hrs post-treatment by dial thickness gage2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID586315Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression at 1 ug/ml after 5 days post infection by quantitative real time RT-PCR2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1128819Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear swelling at 100 mg/kg, ig administered 90 mins prior to xylene challenge measured after 30 mins2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID586322Inhibition of Human T-cell leukemia/lymphoma virus type 1 reverse transcriptase activity infected in human MT2 cells assessed as level of p19 antigen2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1707257Antiproliferative activity against human MCF7 cells incubated for 48 hrs by [3H]-thymidine incorporation assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID586330Ratio of CC50 for PHA-stimulated human PBMC to IC50 for HIV1 infected in human PBMC2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1128810Equilibrium solubility of the compound by classical saturation shake flask method2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID586312Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression at 5 ug/ml after 3 weeks post infection by quantitative real time RT-PCR2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1695497Antiinflammatory activity in ICR mouse model of carrageenan-induced paw edema assessed as paw edema inhibition rate at 50 mg/kg, po pretreated with compound followed by carrageenan challenge and measured after 2 hrs post-treatment by dial thickness gage2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID436155Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of PMA-activated oxidative burst by chemiluminescence assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Oxidative burst inhibitory and cytotoxic indoloquinazoline and furoquinoline alkaloids from Oricia suaveolens.
AID402139Antimalarial activity against Plasmodium falciparum at 50000 ng/ml1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID586321Inhibition of HIV1 3B reverse transcriptase activity infected in human H9 cells assessed as level of p24 antigen2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID586326Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID586319Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression after 3 weeks post infection by quantitative real time RT-PCR2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1128811Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing at 70 mg/kg, ig administered 1 hr before acetic acid challenge measured after 15 mins2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID586327Ratio of zidovudine CC50 to compound CC50 for human MOLT3 cells2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1695484Antiinflammatory activity in mouse model of xylene-induced ear swelling assessed as inhibition of swelling by measuring weight of the ear at 100 mg/kg, ig pretreated for 90 mins followed by xylene challenge and measured after 30 mins relative to control2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID1707258Antiproliferative activity against human MDA-MB-435 cells incubated for 48 hrs by [3H]-thymidine incorporation assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID397122Inhibition of HIV1 RT
AID328118Neuroprotective activity against rat cortical cells at 0.1 uM assessed as glutamate-induced neurotoxicity by MTT assay2008Journal of natural products, Feb, Volume: 71, Issue:2
Neuroprotective limonoids of root bark of Dictamnus dasycarpus.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1128807Dissociation constant, pKa of the compound2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID586324Inhibition of HIV1 3B reverse transcriptase activity2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1695493Antiinflammatory activity in ICR mouse model of carrageenan-induced paw edema assessed as paw edema inhibition rate at 50 mg/kg, po pretreated with compound followed by carrageenan challenge and measured after 3 hrs post-treatment by dial thickness gage2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID436153Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Oxidative burst inhibitory and cytotoxic indoloquinazoline and furoquinoline alkaloids from Oricia suaveolens.
AID586328Ratio of Lamivudine CC50 to compound CC50 for human MOLT3 cells2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID586320Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression after 5 days post infection by quantitative real time RT-PCR2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID586325Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1128817Antiinflammatory activity in mouse assessed as xylene-induced ear swollen extent at 100 mg/kg, ig administered 90 mins prior to xylene challenge measured after 30 mins (Rvb = 132.8 +/-16.3%)2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and pharmacological evaluation of novel limonin derivatives as anti-inflammatory and analgesic agents with high water solubility.
AID586329Ratio of nevirapine CC50 to compound CC50 for human MOLT3 cells2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1695501Antiinflammatory activity in ICR mouse model of carrageenan-induced paw edema assessed as paw edema inhibition rate at 50 mg/kg, po pretreated with compound followed by carrageenan challenge and measured after 1 hr post-treatment by dial thickness gage2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID589117Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID402137Antimalarial activity against Plasmodium falciparum FCR3TC by radioisotope micro dilution assay1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID1695488Analgesic activity in mouse model of acetic-acid-induced writhing assessed as inhibition of writhing numbers at 70 mg/kg, po pretreated with compound followed by acetic acid challenge and measured after 30 mins relative to control2020RSC medicinal chemistry, Jul-01, Volume: 11, Issue:7
A practical synthesis of amino limonin/deoxylimonin derivatives as effective mitigators against inflammation and nociception.
AID1707259Antiproliferative activity against human Panc-28 cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID328116Neuroprotective activity against rat cortical cells assessed as glutamate-induced neurotoxicity by MTT assay2008Journal of natural products, Feb, Volume: 71, Issue:2
Neuroprotective limonoids of root bark of Dictamnus dasycarpus.
AID586323Ratio of IC50 for nevirapine to compound IC50 for Human T-cell leukemia/lymphoma virus type 1 reverse transcriptase activity2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID356428Inhibition of tyrosinase at 333 uM2003Journal of natural products, Sep, Volume: 66, Issue:9
Constituents from the leaves of Phellodendron amurense var. wilsonii and their bioactivity.
AID1101971Antifeedant activity against larvae of Spodoptera frugiperda (fall armyworm) at 100 ppm measured every 30 min for 8 hr by binary choice assay relative to control2002Journal of agricultural and food chemistry, Nov-06, Volume: 50, Issue:23
Citrus limonoids and their semisynthetic derivatives as antifeedant agents against Spodoptera frugiperda larvae. A structure-activity relationship study.
AID436152Immunomodulatory activity in whole blood assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Oxidative burst inhibitory and cytotoxic indoloquinazoline and furoquinoline alkaloids from Oricia suaveolens.
AID436154Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of zymosan-activated oxidative burst by chemiluminescence assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Oxidative burst inhibitory and cytotoxic indoloquinazoline and furoquinoline alkaloids from Oricia suaveolens.
AID1555761Inhibition of P-gp in human Caco2 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in doxorubicin IC50 at 2.2 uM incubated for 24 hrs by MTT assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Natural products as multidrug resistance modulators in cancer.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (154)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (5.19)18.7374
1990's6 (3.90)18.2507
2000's29 (18.83)29.6817
2010's73 (47.40)24.3611
2020's38 (24.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.56 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index62.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (5.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other151 (94.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]